PROGNOSTIC ROLE OF HAEMATOLOGICAL PARAMETERS IN EXTENDED-STAGE SMALL-CELL LUNG CANCER PATIENTS TREATED WITH ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY

López Gómez. A¹, López Galán. M¹, Prado Mel. E¹, López López. M.V¹, López Feijóo. M¹, Flores Moreno. S¹, Jiménez Galán. R¹,


¹ Hospital Universitario Virgen del Rocío, Sevilla

BACKGROUND AND IMPORTANCE

The neutrophil-lymphocyte ratio (NLR) and eosinophil count have been proposed as possible prognostic markers in immunotherapy-treated patients with different tumors types.

OBJECTIVES

To determine the prognostic role of NLR and eosinophil count in patients with extended-stage small-cell lung cancer (ES-SCLC) treated with atezolizumab in combination with chemotherapy.




Retrospective observational study that included patients with ES-SCLC treated with atezolizumab+carboplatin+etoposide between September-2021-December-2023.

Variables collected

- Sex, age
- Eastern Cooperative Oncology Group Stage Performance Status (ECOG PS)
- **Baseline brain or liver metastases**
- **Causes of treatment discontinuation**
- **Neutrophil-lymphocyte ratio and eosinophil count** (EAR) at two time points (baseline and first radiological assessment)
- **Objective response rate** (ORR)

Median progression-free survival (PFS) and overall survival (OS).

Statistical analysis: the Kaplan–Meier method was used for estimating the probability of survival. The log-rank test was used to determine the relationship between each variable and OS. Cox regression model was performed with the variables that had shown statistical significance.



56.7% discontinued treatment due to progression, 21.6% died,8.1% had clinical deterioration and 5.4% due to toxicity.

43.2% had partial response, **24.3%** stable disease, **21.6%** progression and in the remainder response was not assessed

CONCLUSIONS

NLR<3 at the first radiological assessment was identified as an independent predictor of OS in patients with ES- SCLC treated with atezolizumab in combination with chemotherapy.

the presence of brain metastases (p=0.043).

In multivariate analysis, NLR<3 was the only independent predictor variable of OS with median OS 10 months (95% CI:3.05-16.93) vs 5 months (95% CI:3.15-6.85); HR=0.25; p=0.017.



5PSQ-137